Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEVANT-HCC: Regorafenib After Lenvatinib Failure in Unresectable HCC
NCT07514429Phase 2Not yet recruiting
- Start
- Mar 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in hepatocellular carcinoma (HCC). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07514429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514429.